Clinical Trials

Clinical team sharing a computer screen

Program Overview

The Clinical Trials Program has actively engaged in over 30 investigator initiated and pharmaceutical funded clinical trials phased 2-4. Participants for these trials are recruited to help investigate treatments that focus on a new drug, combination of drugs, or a new strategy for existing therapies. Through these trials, the program contributes invaluable information to the field of medical therapy, influencing research and understanding of new ways to better prevent, detect and understand diabetes around the globe.

We are currently seeking participants with Type 2 diabetes for 3 active clinical trial: REMIT-IDegLira; ARISE-HF; and ONWARDS 5. 

For more information about the trial, including eligibility, please contact Marnie Orcutt.

Current Trials  


Our Team is currently running three active studies at our fully-equipped research site, which include: Remit-IDegLira, ONWARDS 3 and ONWARDS 5.

Currently Recruiting


We are seeking individuals with type 2 diabetes to participate in these trials. 
ARISE-HF. The purpose of the ARISE-HF study is to learn about the effects of the study drug in helping to prevent cardiac disease in people with Type 2 diabetes. 
REMIT-IDegLira. The purpose of the REMIT-IDegLira study is to learn more about early diabetes and whether it can be reversed or put into ‘remission’. 
ONWARDS 3. This is a 26 week multi-centre, double- blind trial comparing the effectiveness and safety of once weekly insulin icodec and once daily insulin degludec, both in combination with non-insulin anti-diabetic drugs. 
ONWARDS 5. This is a 52 week multi-centre trial to investigate the effectiveness and safety of once weekly insulin icodec (an investigational insulin taken once weekly) used with DoseGuide.